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Introduction 
It is not the intention of this paper to review in great detail all that is known of the 
“alternative complement pathway”.  There have been several reviews in recent years 
(Bexborn et al 2008; Lachmann 2009; Nilsson and Nilsson-Ekdahl 2012; and 
Harrison 2017;) the last of which in particular goes  into the subject in great detail.  
However, there does appear to remain a degree of misunderstanding of some 
aspects of this pathway particularly in the role of the “tickover” which is still frequently 
shown in diagrams of the alternative pathway as its activating event – which, as is 
discussed below, it is not.  The intention of this paper is to look again at what the 
alternative pathway is and what it does and to suggest that it should be regarded in a 
different light from the classical and lectin pathways, serving in large part as an 
amplification mechanism for all ways of activating the complement system – a 
conclusion similarly reached by Harrison (2017). 
 
History 
What became known as the alternative complement pathway originated with the 
work of the Pillemer laboratory when the first paper on “the properdin system and 
immunity” was published in 1954.  This work gave rise to a series of some fourteen 
papers followed by immense controversy which are comprehensively reviewed by 
Lepow (1980).  It is perhaps just worthwhile with hindsight to look at this early work 
in outline again.  The Pillemer group used zymosan, a preparation of yeast cell walls 
that is pure carbohydrate, as a complement activator.  It was already then known 
that treating human serum at 37oC with zymosan depleted it of what was then called 
“C’3”, which then described all the components needed after C1, 4 and 2 to produce 
lysis.  Treating guinea pig serum with zymosan does remove all C3 (in its 
contemporary sense) so that the resulting reagent, known as “R3”, can be used to 
generate EAC142 when added, in the presence of calcium, to antibody-coated 
erythrocytes.  This is not the case with human serum where the R3 reagent seems to 
exhaust Factor B rather than C3 and the human “R3” does contain appreciable 
amounts of C3.  When used to treat antibody-coated erythrocytes in the presence of 
calcium and magnesium human R3 gives rise to the intermediate EAC1423bi.  None 
of this this was known in the 1950s since C3, the first complement to be isolated as a 
protein, was not described until 1960 (Müller-Eberhard and Nilsson 1960).   
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The observation that formed the basis of the work on properdin was that when 
zymosan was incubated with human serum at 17oC, it removed a component (to 
which the name properdin was given) which was necessary for zymosan to produce 
an R3 reagent at 37oC.  Properdin was subsequently purified by Pensky et al in 1968 
by which time it had also been discovered that there were other components 
required for the fixation of properdin to zymosan to take place.  These were 
recognised as being similar to the classical complement components C1, C4 and C2.  
Looking back at these experiments with the hindsight of over sixty years, it does 
seem to be the case that at 17oC there is a reaction that allows covalent binding of 
C3b to zymosan where it may bind some Factor B (the C2-like component of the 
properdin pathway), and that this then allows the binding of properdin to C3b or 
C3b(B).  The exact nature of the reaction that allows the C3 fixation is still not wholly 
clear.  Pillemer and his group used a resin to deplete cations and showed that they 
needed to restore only magnesium, rather than calcium, in order for this reaction to 
work.  If this resin removed all calcium, then one can exclude the classical pathway 
as being involved.  Otherwise it certainly would be activated, since human serum 
contains antibodies to the many carbohydrate determinants that are found on 
zymosan.  Total absence of calcium would also exclude involvement of much of the 
lectin pathway (which was quite unknown at that time) since the C-type lectins - 
mannose binding lectin, and the collectins - also require calcium for their activity.  On 
the other hand, it is now known that ficolins are another group of proteins that can 
activate the lectin pathway.  These are not C-type lectins but use fibrinogen-type 
recognition domains which, generally, do not require calcium for binding their ligands 
(Garlatti et al 2010).  It is therefore quite plausible that this reaction at 17oC which 
allows the covalent fixation of C3 onto zymosan is mediated by the lectin pathway 
using ficolins.  Furthermore, the discovery by Yaseen et al (2017) that MASP-2, the 
principal enzyme involved in lectin pathway activity going via C4 and C2, can itself 
produce sufficient cleavage of C3 to activate the alternative pathway, provided 
another route by which lectin pathway activation can interact directly with the 
alternative pathway.  It is quite likely, therefore, that what Pillemer was observing 
was due, in part at least, to lectin pathway activation.  It is also possible that it is the 
“protected surface” property of zymosan – its capacity of allowing bound C3b to bind 
Factor B in preference to Factor H – that allows some C3 fixation to occur.  However, 
the C3b amplification loop does not work well at 17oC and in order to get appreciable 
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C3 fixation by such a mechanism one would anticipate the need for a much higher 
temperature.   
 
What generated controversy was, largely, the claims that properdin was a major 
player in innate immunity to viruses, bacteria and tumours.  There is some dispute 
whether Pillemer made these claims in quite the way it was reported in the popular 
press at the time (see the discussion by Colten quoted in Lachmann (2006)but these 
claims certainly raised the profile of the properdin system and also, probably, 
encouraged the scepticism.  The major sceptic was Robert Nelson who in 1958 
published “an alternative mechanism for the properdin system” having previously 
presented his criticisms at meetings.  Nelson’s view was that basically the properdin 
experiments were simply demonstrating the activity of the classical pathway that 
involved antibodies and classical pathway components.  His experiments were, 
however, done in large part on guinea pig serum which, as already mentioned, is not 
an entirely good analogue for human serum with regard to reactions with zymosan 
and certainly what Nelson described would have required the presence of calcium.  
In retrospect, therefore, his criticisms do not look as potent as they were considered 
at the time.   
 
Properdin was shown to act as a stabiliser of the alternative pathway convertase 
C3bBb (Fearon and Austen 1975) and as such has an important physiological role.  
Properdin deficiency is associated with meningococcal infections, as are so many 
other complement deficiencies.  Moreover, it is now established that properdin, as it 
occurs in plasma, reacts only with C3b (Harboe et al 2017) in spite of more recent 
claims (Hourcade et al 2006; Kemper et al 2010) that properdin may act as a 
recognition molecule and therefore could act as an initiator of the complement 
alternative pathway along the lines originally postulated by Pillemer.  However, larger 
polymers of properdin do have some capacity of this type.  These polymers can be 
found in properdin purified from plasma where they are an artefact, as was first 
shown by Farries et al (1987).  However, it has more recently been shown that 
properdin made by recombinant techniques (Ali et al 2014) has similar properties to 
the artefactual properdin polymers and this recombinant properdin has been shown 
to be a powerful stimulant of complement activity by stabilising the C3 convertase.  
Whether properdin found at extravascular sites in vivo, possibly made by 
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polymorphs, may contain or comprise these larger polymers is unknown and it is 
therefore still unclear whether these larger properdin polymers can occur in vivo. 
 
Evolutionary History  
In contrast to its discovery history, in evolutionarily terms the alternative pathway can 
be considered to form the oldest part of the complement system (see Lachmann 
2009 for a more detailed account).  A C3 like molecule can be found in insects and a 
Factor B-like protein in echinoderms.  In these invertebrates the invading micro-
organisms presumably supplied the enzymes needed to cleave C3 and Factor B.  In 
vertebrates with a pumped circulation which contains a wide variety of protease 
inhibitors the remainder of the alternative pathway evolved (see Figure).  
Interestingly, echinoderms were also shown to be able to activate the C3 like 
molecule through analogues of lectin pathway components (Fujita, 2002) indicating 
that a form of  invertebrate lectin pathway by far antedates the classical pathway 
activation route. The appearance of the latter somewhat paralleled the evolutionary 
rise of antibodies, the most potent inducers of classical pathway activation.The 
classical pathway seems to have developed in vertebrates largely by gene 
duplication to provide a feed-in to the alternative pathway particularly from the 
humoral adaptive immune system; and the vertebrate lectin pathway to allow 
activation of the classical pathway using lectins recognising pathogen associated 
carbohydrate determinants and thus providing a further feed-in from the innate 
immune system. 
 
The renaissance of the Alternative Pathway 
The renaissance of the alternative pathway following the controversies of the 1950s 
and early ‘60s came from a quite different direction which was the demonstration that 
there were various ways of activating complement that did not involve the early 
classical pathway components.  Gewurz et al (1968) showed that 
lipopolysaccharides could consume what had been known as C’3 - which by that 
time was known to be all the components from C3 to C9 - without consuming C1 and 
C4.  It was shown that precipitates made with guinea pig IgG1 antibodies (Sandberg 
et al 1970) or with rabbit Fab’2 (Reid 1971) had similar properties.  In 1971, Frank et 
al showed that C4-deficient guinea pig complement was able to be activated using 
suitable activators.  These findings made it amply clear that there was a mechanism 
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of activating the complement system that did not require C1, C4 and C2 and this 
renewed the study of what other components were involved in this pathway.  It had 
already been found that these showed analogy to the classical pathway components.  
There was a C2-like (heat labile) protein which was demonstrated as a novel protein 
by Boenisch and Alper 1970 and who named it glycine-rich beta glycoprotein (GBG).  
A similar protein was described by Götze and Müller-Eberhard in 1971 and was 
called by them C3 proactivator and again by Goodkofsky and Lepow in 1972, from 
what had been the Pillemer laboratory, who called it Factor B by analogy with the 
original Pillemer nomenclature and this name was finally adopted.  There was also a 
C4-like (hydrazine sensitive) protein which was known as properdin Factor A and 
this was demonstrated by Müller-Eberhard and Götze in 1972 to be C3 itself.  A C1-
like component was isolated by Alper and Rosen (1971) who called it glycine-rich 
beta glycoproteinase (GBGase) and the following year by Müller-Eberhard and 
Götze (1972) who called it C3PA convertase.  This protein was subsequently called 
Factor D.   
In the early 1970s these laboratories were of the opinion that this alternative pathway 
would have an initiation rather like the classical pathway and it was speculated that 
this would start, by analogy with the classical pathway, with the activation of Factor D 
from a precursor form (Fearon et al 1979).  The Müller-Eberhard laboratory (Vallota 
et al 1974; Schreiber et al 1976a and b) believed that the initiation event involved a 
novel initiating factor which was a naturally occurring analogue of C3 nephritic 
factors, which had first been described by Spitzer et al (1969).  However, neither of 
these hypotheses turned out to be correct.  There is a zymogen form of Factor D but 
normal serum always contains active Factor D and the activation of the zymogen 
probably occurs largely extra-vascularly near the site of synthesis of Factor D, which 
is largely by adipocytes.  It has recently been demonstrated that the enzyme that is 
largely concerned in this activation is MASP-3 (Dobó et al 2016), one of the enzymes 
of the lectin pathway, and the only one that is resistant to inhibition by C1 inhibitor 
(Zundel et al 2004) and therefore has a prolonged active half-life in vivo.  The 
initiating factor turned out not to exist at all.  Nephritic factors, contrary to the 
vigorous claims of the “La Jolla group” (i.e. Müller-Eberhard and co-workers), are 
indeed immunoglobulins and they are a curious set of autoantibodies to the 
alternative pathway C3 convertase which cause major activation of the complement 
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system.  It is still unknown what causes them to be formed.  They are, however, IgG, 
as first suggested by Thompson (1972), who identified them particularly with IgG3, 
and this was subsequently proven by showing that they pass the placenta (Davis et 
al 1977) and by Scott et al (1978) and Daha and van Es (1979) who showed that 
Fab and Fab’2 fragments of these antibodies retained their biological activity.  Scott 
et al (1981) further showed that these antibodies were unusual in that they are rather 
larger than normal IgG; that this increase in size is due to increased glycosylation; 
and that removal of the carbohydrate with mild periodate treatment causes them to 
lose their biological activity. These “original” nephritic factors will, when purified as 
IgG and added to normal human serum, cause conversion of the C3 in the serum to 
iC3b and subsequently to C3dg and C3c. This reflects the findings in patients with 
these nephritic factors who have C3dg (known earlier as alpha 2D globulin) present 
in their plasma. These effects result from their property of powerfully stabilising the 
alternative pathway C3 convertase (Daha et al 1976).  In more recent years, a new 
definition for nephritic factors was adopted which classifies as nephritic factors all 
antibodies that show some stabilisation of the alternative pathway convertase.  The 
great majority of these do not convert C3 in normal human serum and their biological 
significance is less secure.  One always has to bear in mind that antibodies to C3 
breakdown products occur in response to complement fixation of all kinds and these 
antibodies are known as immunoconglutinins (Coombs et al 1961) so one must 
always be certain that such antibodies are the cause of the complement activation 
rather than its result.   
 
The Alternative Pathway as a purely rate governed reaction 
The recognition that the alternative pathway was quite different from the classical 
pathway – and subsequently from the lectin pathway as well - in having no initiating 
event at all again came from quite different studies.  In 1967, Alper and his 
colleagues in Boston first studied a patient who had powerful continuous 
complement activation in vivo with conversion of C3 to C3b and of Factor B to Bb 
(Alper et al 1970).  It was at that time quite unknown what was the matter with him 
and the possibility of his abnormality being Factor I deficiency was discussed when 
Chester Alper and I met at the 17th Protides of the Biological Fluids meeting in 1969, 
Factor I having been discovered in 1966 as an enzymatic component of plasma that 
was required to convert C3b (which had been found not to react with bovine 
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conglutinin) to another C3 breakdown product, C3bi, that would do so (Lachmann 
and Müller-Eberhard 1968).  The Boston patient, TJ, did turn out to be Factor I 
deficient and this was the cause of the continuous activation of his alternative 
pathway.  It was subsequently shown (Nicol and Lachmann 1973) that exactly the 
same situation could be produced in vitro by the depletion of Factor I from normal 
human serum using purified Fab2’ antibodies.  When such depleted serum is 
warmed up, there is immediate and virtually complete conversion of C3 to C3b.  
From these observations came the realisation that the alternative pathway is a rate-
governed reaction where two competing pathways act upon C3b.  One, 
subsequently found to involve Factor H as well as Factor I (Whaley and Ruddy 
1976), leads to the breakdown of C3b to iC3b and destroys the possibility of 
feedback, whereas the other is the C3b feedback cycle where C3b combines with 
Factor B and is acted upon by Factor D and gives rise to C3bBb, the alternative 
pathway C3 convertase (see Figure 1).  
 
The C3-tickover 
It was apparent on looking at this model that there had to be a mechanism to provide 
a miniscule amount of C3b, or some analogous protein, present at all times so that 
simply removing Factor I (or Factor H) could activate the pathway. This was given 
the name of the “C3 tickover” (Lachmann and Nicol 1974; Lachmann and Halbwachs 
1975) by analogy with a car engine that has to be ticking over before pressing the 
accelerator causes the car to move.  At the time, it was thought that small amounts 
of C3 conversion to C3b by a variety of enzymes, including other complement 
enzymes, would be the cause.   
 
The whole idea was greatly resisted by the La Jolla group when it was first presented 
to the Coronado Complement workshop in 1973 and they continued to publish about 
an initiating factor for some years thereafter. However, in 1981 Pangburn et al 
suggested, without actually mentioning the tickover hypothesis, that the initial C3 
product might be a spontaneous hydrolysis product breaking the internal thioester 
bond and that this product, iC3, was capable of reacting in both the breakdown and 
amplification loops.  This is an attractive and plausible idea though very difficult to 
prove.  The essence of the tickover is that there are tiny amounts of either C3b or 
iC3 present at all times which do not themselves cause complement activation and 
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presumably are rapidly converted to iC3b and iC3i; and which can allow complement 
activation in the absence of other complement pathway activity 
 
The Protected Surface 
The “protected surface” phenomenon described by Fearon and Austen (1977) is 
certainly the essential mechanism for giving rise to alternative pathway activation in 
the absence of the activity of the other complement pathways.  This term describes 
the phenomenon whereby C3b bound on certain surfaces is relatively resistant to 
binding Factor H while continuing to bind Factor B normally thereby promoting the 
C3b amplification loop.  These protected surfaces were typically carbohydrates 
lacking sialic acid (Kazatchkine et al 1979) but these are by no means the only 
products to do this.  Zymosan, as used by Pillemer and everybody else ever since, is 
a canonical protected surface as is particulate inulin and as is bacterial 
lipopolysaccharide of the smooth variety.  In the case of inulin, it is of particular 
interest that soluble inulin does not have a protected surface effect suggesting that it 
does need to be an insoluble surface.  Smooth lipopolysaccharides containing 
carbohydrates may well be the most important in vivo activator by this mechanism 
and Gram negative infections acting in this way may be of considerable importance 
in a number of diseases.  The “rough” endotoxin - Lipid A - binds C1q and activates 
the classical pathway (Lachmann and Nicol 1974) so that endotoxins may recruit the 
alternative pathway by two complementary mechanisms.  
 
There are other protected surfaces that are important during complement activation. 
One of these is IgG. C3b, or presumably iC3, bound to IgG is protected as shown by 
Sissons et al (1979) and by Reiter and Fishelson (1989).  This is important in 
allowing the classical pathway to feed efficiently into the C3b feedback loop.  
Furthermore, as shown by Meri and Pangburn (1990) in an important but seldom 
quoted paper, C3 bound covalently to the classical pathway convertase, C4b2b, is 
also protected and this enables it efficiently to give rise to a C5 convertase as well as 
potentially stimulating feedback.  This property seems not to be shared by C3b 
bound to the alternative pathway convertase, C3bBb, and this would explain the 
greatly increased lytic efficiency of the classical pathway over the alternative 
pathway.  No other explanation for this phenomenon had ever really been adduced.   
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That it is necessary for C3 to be bound onto an insoluble surface for the activation of 
the alternative pathway (Nilsson and Nilsson Ekdahl 2012) is true for activation via 
the protected surface but is not necessary for activation by the depletion of Factor I 
or Factor H or the addition of nephritic factors to serum in vitro all of which can 
activate the C3 feedback loop to exhaustion entirely in the fluid phase.   
 
Factor H deficiency produces a somewhat similar phenotype to Factor I deficiency 
although other Factor I co-factors do allow the production of iC3b from C3b.  This 
has important consequences because the reaction of iC3b with CR3 on neutrophils 
is an essential mechanism for complement-mediated immunopathology. This occurs 
in Factor H deficiency but not in Factor I deficiency (Rose et al 2008). 
 
It therefore is probably accurate to regard the C3b amplification and feedback loops 
as an amplification mechanism for all forms of complement activation, be it by the 
classical pathway or by the lectin pathway or by the presence of nephritic factors, 
and that it is only the protected surface phenomenon which gives it status as an 
autonomous pathway of complement activation in-vivo. It is the protected surface 
rather than the tickover which should be shown as “initiating” activation by the 
alternative pathway. 
In vivo there are likely to be many situations where the recruitment of the 
amplification loop via the classical pathway or the lectin pathway are as important.  
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